BioPharmSignal logoBioPharmSignal

Biotech News

Organogenesis Announces Initiation of Biologics License Application for ReNu®

Organogenesis (ORGO)Organogenesis2026-06-25 13:46 ESTFDA / regulatory

Initial modules submitted to FDA under rolling review; final modules expected in the first half of 2026 CANTON, Mass., Dec. 23, 2025 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture and commercialization

Open original release

Related news

ORGOOrganogenesis2026-06-25 13:46 EST

Organogenesis Holdings Inc. Reports First Quarter 2026 Financial Results

ORGOOrganogenesis2026-06-25 13:46 EST

Organogenesis Holdings Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

ORGOOrganogenesis2026-06-25 13:46 EST

Organogenesis Applauds CMS’s Significant Step In Payment Reform

ORGOOrganogenesis2026-06-25 13:46 EST

Organogenesis Holdings Inc. Reports Third Quarter 2025 Financial Results, Posts Record Revenue and Raises 2025 Guidance

ORGOOrganogenesis2026-06-25 13:46 EST

Organogenesis Announces Successful FDA Meeting and Plan to File BLA for ReNu® for Knee Osteoarthritis Pain

ORGOOrganogenesis2026-06-25 13:46 EST

Organogenesis Holdings Inc. to Report Fourth Quarter and Fiscal Year 2025 Financial Results on February 26, 2026

ORGOOrganogenesis2026-06-25 13:46 EST

Organogenesis Holdings Inc. Reports Fourth Quarter 2025 Financial Results, Posts Record Revenue

ORGOOrganogenesis2026-06-25 13:46 EST

Organogenesis Holdings Inc. to Report First Quarter of Fiscal Year 2026 Financial Results on May 7, 2026

ORGOOrganogenesis2026-06-25 13:46 EST

Organogenesis Achieves Primary Endpoint in Randomized Controlled Trial of PuraPly®AM

ORGOOrganogenesis2026-06-25 13:46 EST

Organogenesis Completes Rolling Submission of Biologics License Application for ReNu®

View all latest news

Organogenesis

Organogenesis is a biopharmaceutical company focused on advancing a pipeline of therapeutic programs. Investors usually track how clinical data, regulatory milestones, and launch execution change the story over time.

Recent company news

ORGOOrganogenesis2026-06-26 10:41 EST

Organogenesis Holdings Inc. Reports First Quarter 2026 Financial Results

ORGOOrganogenesis2026-06-26 10:41 EST

Organogenesis Holdings Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

ORGOOrganogenesis2026-06-26 10:41 EST

Organogenesis Applauds CMS’s Significant Step In Payment Reform

ORGOOrganogenesis2026-06-26 10:41 EST

Organogenesis Holdings Inc. Reports Third Quarter 2025 Financial Results, Posts Record Revenue and Raises 2025 Guidance

ORGOOrganogenesis2026-06-26 10:41 EST

Organogenesis Announces Successful FDA Meeting and Plan to File BLA for ReNu® for Knee Osteoarthritis Pain

Stock data

Close
—
Market cap
—
Exchange
NASDAQ
Sector
Biotechnology
Location
United States